The licensing agreement that was announced in conjunction with resolution of legal proceeding is expected to deliver benefits to cancer patients in addition to delivering financial benefits to Agios, Penn and the Abramson Family Cancer Research Institute.
Agios chief executive officer David Schenkein said, "We are pleased to be collaborating with Penn and value the contributions of their scientists to this exciting field."
Penn the Abramson Cancer Center director and professor of medicine Chi Van Dang said the university is moving forward in a collaborative manner around newly identified intellectual property.
"We look forward to working with Agios on this project and potentially other unrelated projects in the future," Chi Van Dang added.